Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALT Stock Forecast 2025-2026
$5.07
Current Price
$398.16M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ALT Price Targets
+452.3%
To High Target of $28.00
+393.1%
To Median Target of $25.00
+136.7%
To Low Target of $12.00
ALT Price Momentum
+5.8%
1 Week Change
-4.7%
1 Month Change
-30.2%
1 Year Change
-29.7%
Year-to-Date Change
-54.6%
From 52W High of $11.16
+42.7%
From 52W Low of $3.55
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Altimmune (ALT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALT and similar high-potential opportunities.
Latest ALT Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ALT has a bullish consensus with a median price target of $25.00 (ranging from $12.00 to $28.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $5.07, the median forecast implies a 393.1% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Patrick Trucchio at HC Wainwright & Co., suggesting a 136.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALT Analyst Ratings
8
Buy
1
Hold
0
Sell
ALT Price Target Range
Low
$12.00
Average
$25.00
High
$28.00
Current: $5.07
Latest ALT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Apr 2, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
| Mar 18, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Mar 14, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Feb 28, 2025 | William Blair | Andy Hsieh | Market Perform | Initiates | $0.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jan 8, 2025 | Stifel | Annabel Samimy | Buy | Initiates | $18.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Nov 12, 2024 | UBS | Eliana Merle | Buy | Initiates | $26.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| Aug 12, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $20.00 |
| Jun 25, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $20.00 |
| Jun 21, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $25.00 |
| May 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $12.00 |
| May 10, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $24.00 |
| Apr 29, 2024 | Guggenheim | Seamus Fernandez | Neutral | Downgrade | $0.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $12.00 |
Altimmune, Inc. (ALT) Competitors
The following stocks are similar to Altimmune based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ALT
Altimmune
mkt cap
398.16M
Altimmune, Inc. (ALT) Financial Data
Altimmune, Inc. has a market capitalization of $398.16M with a P/E ratio of -3.8x. The company generates $20,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -86.5% quarter-over-quarter, while maintaining an operating margin of -497,320.0% and return on equity of -59.9%.
Valuation Metrics
Market Cap
$398.16M
Enterprise Value
$260.25M
P/E Ratio
-3.8x
PEG Ratio
-3.4x
Price/Sales
19,908.0x
Growth & Margins
Revenue Growth (YoY)
-86.5%
Gross Margin
N/A
Operating Margin
-497,320.0%
Net Margin
0.0%
EPS Growth
-86.5%
Financial Health
Cash/Price Ratio
+33.8%
Current Ratio
13.1x
Debt/Equity
1.4x
ROE
-59.9%
ROA
-36.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Altimmune, Inc. (ALT) Business Model
About Altimmune, Inc.
What They Do
Develops immunotherapeutics for unmet medical needs.
Business Model
Altimmune, Inc. operates in the biopharmaceutical sector, focusing on developing proprietary therapeutic candidates aimed at treating liver disease, obesity, and infectious diseases. The company generates revenue through the advancement of its innovative pipeline, which includes unique non-invasive delivery methods that enhance therapeutic potential and patient compliance.
Additional Information
Headquartered in Gaithersburg, Maryland, Altimmune is positioned at the forefront of biopharmaceutical innovation, contributing to the development of cutting-edge treatments in the healthcare sector. Its efforts are significant in addressing critical health issues, with potential impacts on global health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Dr. Vipin K. Garg Ph.D.
Country
United States
IPO Year
2000
Website
altimmune.comAltimmune, Inc. (ALT) Latest News & Analysis
Latest News
Quick Summary
Valuation is a key factor in investing, and there are opportunities to find stocks that are considered great bargains.
Why It Matters
Valuation impacts investment returns. Identifying undervalued stocks can lead to significant profits, making them attractive opportunities for savvy investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Altimmune, Inc. expects top-line data from its phase 2b IMPACT study on pemvidutide for MASH in Q2 2025. The NASH market could reach $39.3B by 2031. FDA cleared IND for two mid-stage studies on AUD and ALD.
Why It Matters
Altimmune's upcoming data on pemvidutide and FDA clearance for mid-stage studies highlight potential market growth in NASH, AUD, and ALD, signaling opportunities for revenue and stock price increases.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Altimmune plans to test its obesity drug, pemvidutide, for treating alcohol use disorder and alcohol-associated liver disease.
Why It Matters
Altimmune's expansion of pemvidutide trials into alcohol-related conditions could diversify its market potential, impacting stock value and investor interest in the company's growth trajectory.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Pemvidutide has received recent IND clearances from the FDA, and a program will showcase presentations from key opinion leaders in obesity, MASH, and two other indications.
Why It Matters
FDA clearances for Pemvidutide indicate potential market expansion and increased revenue opportunities, boosting investor confidence in related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Altimmune, Inc. (Nasdaq: ALT) will have its management team participate in a fireside chat at the Leerink Global Healthcare Conference on March 3, 2025.
Why It Matters
Altimmune's participation in a major healthcare conference can influence investor sentiment, showcasing its visibility and potentially leading to new partnerships or funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
2 months ago
Quick Summary
Altimmune's pemvidutide shows potential for treating MASH and obesity, boosting investor interest. Q4 2024 earnings reported a $23.2M loss, with $131.9M in cash for ongoing operations.
Why It Matters
Altimmune's pemvidutide could disrupt the obesity and liver health market, attracting investor interest. However, ongoing losses and cash reliance highlight risks tied to clinical outcomes.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ALT Stock
What is Altimmune, Inc.'s (ALT) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Altimmune, Inc. (ALT) has a median price target of $25.00. The highest price target is $28.00 and the lowest is $12.00.
Is ALT stock a good investment in 2025?
According to current analyst ratings, ALT has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALT stock?
Wall Street analysts predict ALT stock could reach $25.00 in the next 12 months. This represents a 393.1% increase from the current price of $5.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Altimmune, Inc.'s business model?
Altimmune, Inc. operates in the biopharmaceutical sector, focusing on developing proprietary therapeutic candidates aimed at treating liver disease, obesity, and infectious diseases. The company generates revenue through the advancement of its innovative pipeline, which includes unique non-invasive delivery methods that enhance therapeutic potential and patient compliance.
What is the highest forecasted price for ALT Altimmune, Inc.?
The highest price target for ALT is $28.00 from at , which represents a 452.3% increase from the current price of $5.07.
What is the lowest forecasted price for ALT Altimmune, Inc.?
The lowest price target for ALT is $12.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 136.7% increase from the current price of $5.07.
What is the overall ALT consensus from analysts for Altimmune, Inc.?
The overall analyst consensus for ALT is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are ALT stock price projections?
Stock price projections, including those for Altimmune, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:49 AM UTC